Ipsen (ENXTPA:IPN) - Stock Price, News & Analysis

IPN Stock Overview

Ipsen S.A. operates as a biopharmaceutical company worldwide.

IPN fundamental analysis
Snowflake Score
Valuation	5/6
Future Growth	1/6
Past Performance	1/6
Financial Health	6/6
Dividends	4/6

Rewards

Trading at 34.3% below our estimate of its fair value

Earnings are forecast to grow 5.24% per year

Risk Analysis

Large one-off items impacting financial results

My Notes

Capture your thoughts, links and company narrative

Ipsen S.A. Competitors

Virbac

ENXTPA:VIRP

€2.5b

Vetoquinol

ENXTPA:VETO

€1.0b

Sanofi

ENXTPA:SAN

€117.8b

Boiron

ENXTPA:BOI

€669.5m

Price History & Performance

Summary of all time highs, changes and price drops for Ipsen
Historical stock prices
Current Share Price	€108.50
52 Week High	€115.00
52 Week Low	€80.00
Beta	0.72
1 Month Change	-1.36%
3 Month Change	1.59%
1 Year Change	16.42%
3 Year Change	49.45%
5 Year Change	-20.16%
Change since IPO	357.81%

Recent updates

Ipsen's (EPA:IPN) Dividend Will Be €1.20

May 12

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Mar 19

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Mar 01

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Jan 19

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Dec 08

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Nov 02

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Oct 14

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

Aug 01

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Jul 10

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

May 26

Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

May 04

Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20

Apr 19

Is Ipsen (EPA:IPN) A Risky Investment?

Apr 18

Here's Why I Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Mar 18

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 50% Undervaluation?

Feb 14

Ipsen (EPA:IPN) Has A Rock Solid Balance Sheet

Nov 04

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Aug 05

Ipsen S.A. (EPA:IPN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Jul 15

Earnings Beat: Ipsen S.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 18

An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 49% Undervalued

Apr 05

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Mar 16

We Think Ipsen's (EPA:IPN) Healthy Earnings Might Be Conservative

Feb 22

Should Ipsen (EPA:IPN) Be Disappointed With Their 59% Profit?

Feb 08

Here's What Ipsen S.A.'s (EPA:IPN) Shareholder Ownership Structure Looks Like

Jan 12

An Intrinsic Calculation For Ipsen S.A. (EPA:IPN) Suggests It's 34% Undervalued

Dec 16

Ipsen S.A. (EPA:IPN) Is Yielding 1.3% - But Is It A Buy?

Nov 25

Shareholder Returns

	IPN	FR Pharmaceuticals	FR Market
7D	-3.6%	-6.4%	-1.6%
1Y	16.4%	-4.8%	12.9%

Return vs Industry: IPN exceeded the French Pharmaceuticals industry which returned -1.4% over the past year.

Return vs Market: IPN exceeded the French Market which returned 12.4% over the past year.

Price Volatility

Is IPN's price volatile compared to industry and market?
IPN volatility
IPN Average Weekly Movement	2.7%
Pharmaceuticals Industry Average Movement	3.4%
Market Average Movement	4.4%
10% most volatile stocks in FR Market	8.7%
10% least volatile stocks in FR Market	2.6%

Stable Share Price: IPN is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: IPN's weekly volatility (3%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1929	5,072	David Loew	https://www.ipsen.com

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Dysport for motor muscular disorders and medical aesthetics; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; and Tazverik to treat third-line follicular lymphoma.

Ipsen S.A. Fundamentals Summary

How do Ipsen's earnings and revenue compare to its market cap?
IPN fundamental statistics
Market Cap	€8.97b
Earnings (TTM)	€593.20m
Revenue (TTM)	€3.16b

15.1x

P/E Ratio

2.8x

P/S Ratio

Is IPN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
IPN income statement (TTM)
Revenue	€3.16b
Cost of Revenue	€527.70m
Gross Profit	€2.63b
Other Expenses	€2.04b
Earnings	€593.20m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

Jul 27, 2023

Earnings per share (EPS)	7.18
Gross Margin	83.28%
Net Profit Margin	18.79%
Debt/Equity Ratio	19.8%

How did IPN perform over the long term?

See historical performance and comparison

Dividends

1.1%

Current Dividend Yield

17%

Payout Ratio

Does IPN pay a reliable dividends?

See IPN dividend history and benchmarks

When do you need to buy IPN by to receive an upcoming dividend?
Ipsen dividend dates
Ex Dividend Date	Jun 02 2023
Dividend Pay Date	Jun 06 2023
Days until Ex dividend	2 days
Days until Dividend pay date	6 days

Does IPN pay a reliable dividends?

See IPN dividend history and benchmarks

IPN Stock Overview

Rewards

Risk Analysis

Ipsen S.A. Competitors

ENXTPA:VIRP

€2.5b

ENXTPA:VETO

€1.0b

ENXTPA:SAN

€117.8b

ENXTPA:BOI

€669.5m

Price History & Performance

Recent News & Updates

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen's (EPA:IPN) Dividend Will Be €1.20

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Recent updates

Upcoming dividend of €1.20 per share at 1.1% yield

Ipsen's (EPA:IPN) Dividend Will Be €1.20

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. (EPA:IPN) Shares Could Be 48% Below Their Intrinsic Value Estimate

Ipsen (EPA:IPN) Has A Pretty Healthy Balance Sheet

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen (EPA:IPN) Ticks All The Boxes When It Comes To Earnings Growth

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 46% Undervaluation?

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Does Ipsen (EPA:IPN) Deserve A Spot On Your Watchlist?

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Does Ipsen (EPA:IPN) Have A Healthy Balance Sheet?

First half 2022 earnings released

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Here's Why We Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen (EPA:IPN) Will Pay A Larger Dividend Than Last Year At €1.20

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Upcoming dividend of €1.20 per share

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Ipsen (EPA:IPN) Is Increasing Its Dividend To €1.20

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen's (EPA:IPN) Dividend Will Be Increased To €1.20

Is Ipsen (EPA:IPN) A Risky Investment?

Here's Why I Think Ipsen (EPA:IPN) Might Deserve Your Attention Today

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Is There An Opportunity With Ipsen S.A.'s (EPA:IPN) 50% Undervaluation?

Full year 2021 earnings: EPS exceeds analyst expectations

Ipsen S.A. Proposes Dividend for the Year 2021

Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva

Investor sentiment deteriorated over the past week

Ipsen (EPA:IPN) Has A Rock Solid Balance Sheet

Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-Submit Following Additional Data Analyses

We Think Ipsen (EPA:IPN) Can Manage Its Debt With Ease

First half 2021 earnings released: EPS €3.66 (vs €2.65 in 1H 2020)

Consensus forecasts updated

Ipsen S.A. (EPA:IPN) Shares Could Be 42% Below Their Intrinsic Value Estimate

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen S.A. Confirms U.S. Fda Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (Fop)

Upcoming dividend of €1.00 per share

Ipsen Opts-In to Join Exelixis, Inc With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results

Earnings Beat: Ipsen S.A. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Full year 2020 earnings released: EPS €6.56 (vs €0.66 loss in FY 2019)